| Size | Price | |
|---|---|---|
| 500mg | ||
| 1g | ||
| Other Sizes |
| ADME/Pharmacokinetics |
Metabolism / Metabolites
Hepatic metabolism. Omeprazole is primarily metabolized via the cytochrome P450 (CYP) enzyme system. The two main CYP isoenzymes involved are CYP2C19 and CYP3A4. Metabolism is stereoselective, with the S-isomer being converted to 5'-O-demethylomeprazole via CYP2C19. CYP3A4 converts the S-isomer to 3-hydroxyomeprazole. The R-isomer is converted to 5-hydroxyomeprazole via CYP2C19. CYP3A4 then converts the R-isomer to four different metabolites: 5-hydroxyomeprazole (5-OH OME), omeprazole sulfone (OME sulfone), 5'-O-demethylomeprazole (5'-demethylOME), and 3-hydroxyomeprazole (3-OH OME). Excretion pathway: Urinary excretion is the main route of excretion for omeprazole metabolites. Almost no unchanged drug is excreted in the urine. The majority of the dose (approximately 77%) is excreted in the urine as at least six metabolites. Two of these metabolites have been identified as hydroxyomeprazole and its corresponding carboxylic acid. The remaining dose is excreted in the feces. Half-life: 0.5–1 hour (healthy subjects, extended-release capsules); 3 hours (hepatic impairment). |
|---|---|
| Toxicity/Toxicokinetics |
Toxicity Summary
Omeprazole is a proton pump inhibitor that suppresses gastric acid secretion by specifically inhibiting H+/K+-ATPase in gastric parietal cells. Omeprazole reduces gastric acidity by specifically acting on the proton pump, blocking the final step in gastric acid production. |
| References | |
| Additional Infomation |
Esomeprazole magnesium is the magnesium salt of esomeprazole, which is the S-isomer of omeprazole. It possesses gastric proton pump inhibitor activity. In the acidic environment of parietal cells, esomeprazole is protonated and converted into an active achiral sulfonamide. The active sulfonamide forms one or more covalent disulfide bonds with the proton pump potassium hydrogen ATPase (H+/K+ ATPase), thereby inhibiting its activity and preventing parietal cells from secreting H+ ions into the gastric lumen, the final step in gastric acid production. H+/K+ ATPase is an integrated membrane protein of gastric parietal cells. Esomeprazole sodium is the sodium salt of omeprazole and also possesses gastric proton pump inhibitor activity. In the acidic environment of parietal cells, esomeprazole is protonated and converted into an active achiral sulfonamide. The active sulfinamide forms one or more covalent disulfide bonds with the proton pump potassium hydrogen adenosine triphosphatase (H+/K+ ATPase), thereby inhibiting its activity and thus preventing parietal cells from secreting H+ ions into the gastric lumen, the final step in gastric acid production. H+/K+ ATPase is an integrated membrane protein of gastric parietal cells. Omeprazole magnesium is the magnesium salt form of a benzimidazole compound, exhibiting selective and irreversible proton pump inhibitory activity. In the acidic environment of parietal cells, omeprazole is protonated and converted into an active achiral sulfinamide; this active sulfinamide forms one or more covalent disulfide bonds with the proton pump potassium adenosine triphosphatase (H+/K+ ATPase), thereby inhibiting its activity and subsequently inhibiting the secretion of H+ ions into the gastric lumen by parietal cells, the final step in gastric acid production. H+/K+ ATPase is an integrated membrane protein of gastric parietal cells. Omeprazole S-isomer. See also: Omeprazole magnesium (preferred); Omeprazole (containing the active moiety); Amoxicillin; Omeprazole magnesium; Rifabutin (component).
|
| Molecular Formula |
C34H36MGN6O6S2
|
|---|---|
| Molecular Weight |
713.121
|
| Exact Mass |
712.198
|
| CAS # |
95382-33-5
|
| Related CAS # |
Omeprazole;73590-58-6;Omeprazole sodium;95510-70-6;Omeprazole-d3;922731-01-9;Esomeprazole magnesium;161973-10-0
|
| PubChem CID |
5311083
|
| Appearance |
Typically exists as solid at room temperature
|
| Boiling Point |
600ºC at 760mmHg
|
| Flash Point |
316.7ºC
|
| LogP |
3.765
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
14
|
| Rotatable Bond Count |
10
|
| Heavy Atom Count |
49
|
| Complexity |
993
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
O=S(CC1=NC=C(C(OC)=C1C)C)C2=NC3=C(N2)C=CC(OC)=C3.[Mg]
|
| InChi Key |
KWORUUGOSLYAGD-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/2C17H18N3O3S.Mg/c2*1-10-8-18-15(11(2)16(10)23-4)9-24(21)17-19-13-6-5-12(22-3)7-14(13)20-17;/h2*5-8H,9H2,1-4H3;/q2*-1;+2
|
| Chemical Name |
magnesium;5-methoxy-2-[(4-methoxy-3,5-dimethylpyridin-2-yl)methylsulfinyl]benzimidazol-1-ide
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.4023 mL | 7.0114 mL | 14.0229 mL | |
| 5 mM | 0.2805 mL | 1.4023 mL | 2.8046 mL | |
| 10 mM | 0.1402 mL | 0.7011 mL | 1.4023 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Link: https://clinicaltrials.gov/ct2/show/NCT00674115
Conditions:Gastric Acid|Human ExperimentationLink: https://clinicaltrials.gov/ct2/show/NCT00765206
Conditions:Gastric Acid|Human ExperimentationLink: https://clinicaltrials.gov/ct2/show/NCT01337804
Conditions:Heartburn
Title:Comparison of Prilosec Over-the-counter (OTC)® Versus Prevacid® for Gastric Acid Suppression
Status:Completed
updateDate:2010-12-31
Ctid:NCT00903448
Link: https://clinicaltrials.gov/ct2/show/NCT00903448
Conditions:HealthyLink: https://clinicaltrials.gov/ct2/show/NCT00079833
Conditions:Zollinger-Ellison SyndromeLink: https://clinicaltrials.gov/ct2/show/NCT00206024
Conditions:HeartburnProducts are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
